A genome-wide comprehensive analysis of alterations in driver genes in non-small-cell lung cancer

Anti-cancer Drugs
Jun YiRui Wang

Abstract

Lung cancer is one of the most common malignancies and the leading cause of cancer-related deaths worldwide. Although many oncogenes and tumor suppressors have been uncovered in the past decades, the pathogenesis and mechanisms of lung tumorigenesis and progression are unclear. The advancement of high-throughput sequencing technique and bioinformatics methods has led to the discovery of some unknown important protein-coding genes or noncoding RNAs in human cancers. In this study, we tried to identify and validate lung cancer driver genes to facilitate the diagnosis and individualized treatment of patients with this disease. To analyze distinct gene profile in lung cancer, the RNA sequencing data from TCGA and microarray data from Gene Expression Omnibus were used. Then, shRNA-pooled screen data and CRISPR-Cas9-based screen data in lung cancer cells were used to validate the functional roles of identified genes. We found that thousands of gene expression patterns are altered in lung cancer, and genomic alterations contribute to the dysregulation of these genes. Furthermore, we identified some potential lung cancer driver genes, such as TBX2, MCM4, SLC2A1, BIRC5, and CDC20, whose expression is significantly upregulated in lung ca...Continue Reading

References

Dec 30, 1961·Nature·F H CRICKR J WATTS-TOBIN
May 7, 2004·The New England Journal of Medicine·Brian C Jacobson
Jan 5, 2007·The New England Journal of Medicine·Hsuan-Yu ChenPan-Chyr Yang
Feb 22, 2007·Current Molecular Medicine·Ignacio I Wistuba
Jan 1, 2009·Cancer Biomarkers : Section a of Disease Markers·Amanda Tufman, Rudolph Maria Huber
Aug 4, 2010·Journal of the National Comprehensive Cancer Network : JNCCN·David S EttingerUNKNOWN NCCN Non-Small Cell Lung Cancer Panel Members
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Aug 13, 2013·Cancer Treatment Reviews·Cesare GridelliFortunato Ciardiello
Aug 27, 2013·Lancet·Rafael RosellNiki Karachaliou
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Apr 1, 2015·Cancer Treatment Reviews·Steven L WoodAnthony D Whetton
Apr 10, 2015·Nature Reviews. Genetics·Ophir ShalemFeng Zhang
May 15, 2015·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Hiroyuki Mano
Jun 17, 2015·Proceedings of the National Academy of Sciences of the United States of America·Martin KampmannJonathan S Weissman
Jan 26, 2016·CA: a Cancer Journal for Clinicians·Wanqing ChenJie He
Feb 24, 2016·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Chee-Seng TanRoss A Soo
Mar 31, 2016·Cancer Science·Motonobu SaitoTakashi Kohno
Jun 5, 2016·Cancer Discovery·Andrew J AguirreWilliam C Hahn
Nov 16, 2016·ESMO Open·Floriana MorgilloFortunato Ciardiello
Dec 13, 2016·Lancet·Sibylle Loibl, Luca Gianni
Jan 13, 2017·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Robert Roskoski
Feb 10, 2017·Clinical Laboratory·Ran ChenYue-Dong Gao

❮ Previous
Next ❯

Citations

Jul 8, 2018·International Journal of Cancer. Journal International Du Cancer·Giorgia SimonettiGiovanni Martinelli
Aug 20, 2019·Trends in Molecular Medicine·Chunyang JiangZhigang Zhao
May 18, 2020·Advanced Drug Delivery Reviews·Tao Wan, Yuan Ping
Jan 21, 2022·The Kaohsiung Journal of Medical Sciences·Hao HuChang-Ying Guo

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.